Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Linperlisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib
    Yingli Pharma presents a pivotal Phase 2 study data evaluating linperlisib

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yingli-pharma-presents-a-pivotal-phase-2-study-data-evaluating-linperlisib-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-in-an-oral-session-at-the-american-society-of-hematology-2023-annual-meeting-302010879.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share
    Yingli Pharma Announces presentation on Phase 2 clinical trial of linperlisib
    Yingli Pharma Announces presentation on Phase 2 clinical trial of linperlisib

    10 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

    PRNEWSWIRE
    10 Jun 2021
    Share Share
    Yingli Pharma Announces presentation on Phase 2 clinical trial of linperlisib
    Yingli Pharma Announces presentation on Phase 2 clinical trial of linperlisib

    10 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

    PRNEWSWIRE
    10 Jun 2021
    Share Share
    Yingli Pharma Announces presentation on Phase 2 clinical trial of linperlisib
    Yingli Pharma Announces presentation on Phase 2 clinical trial of linperlisib

    10 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

    PRNEWSWIRE
    10 Jun 2021
    Share Share
    Yingli Pharma to present on the Phase 2 clinical trial of linperlisib
    Yingli Pharma to present on the Phase 2 clinical trial of linperlisib

    10 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html

    PRNEWSWIRE
    10 Jun 2021
    Share Share